Results 61 to 70 of about 43,902 (289)

A novel sequential treatment approach between denosumab and romosozumab in patients with severe osteoporosis

Osteoporosis International
In severe osteoporosis, the optimal approach for sequential treatment between denosumab and romosozumab is unclear. We utilised a novel overlapping strategy in three patients with very-high fracture risk despite long-term denosumab which led to greater ...
Shejil Kumar, M. Gild, Michelle M. McDonald, Albert S. Kim, Roderick J. Clifton-Bligh, Christian M. Girgis   +5 more
semanticscholar   +1 more source

Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases

Journal of Bone and Mineral Research, 2021
A rebound of osteoclast activity during the 2 years after a treatment or prevention of osteoporosis with denosumab (Dmab) leads to an increased risk of vertebral fractures (VFs).
P. Burckhardt, M. Faouzi, T. Buclin, O. Lamy   +3 more
semanticscholar   +1 more source

Comparative effectiveness of denosumab vs alendronate among postmenopausal women with osteoporosis

Journal of Bone and Mineral Research
Although clinical trials have shown that denosumab significantly increases bone mineral density at key skeletal sites more than oral bisphosphonates, evidence is lacking from head-to-head randomized trials evaluating fracture outcomes. This retrospective
J. Curtis, T. Arora, Ye Liu, Tzu-Chieh Lin, L. Spangler, Vanessa C Brunetti, R. Stad, M. Mcdermott, B. Bradbury, Min Kim   +9 more
semanticscholar   +1 more source

The Efficacy of Denosumab in Patients With Rheumatoid Arthritis: A Systematic Review and Pooled Analysis of Randomized or Matched Data

Frontiers in Immunology, 2022
Objective The purpose of this study was to evaluate the efficacy of denosumab treatment in patients with rheumatoid arthritis (RA). Methods The Medline, Embase and Cochrane Library databases were searched for relevant clinical studies.
Q. Hu, X. Zhong, H. Tian, P. Liao
semanticscholar   +1 more source

Activity of eribulin mesylate in brain metastasis from breast cancer. a stone in a pond? [PDF]

, 2018
Background: Brain metastases develop in approximately 10-25% of patients with metastatic breast cancer (MBC) and are associated with a very poor prognosis.
Catania, G., Cognetti, F., Fabi, A., Gasparro, S., Malaguti, P., Vidiri, A.   +5 more
core   +1 more source

Romosozumab added to ongoing denosumab in postmenopausal osteoporosis, a prospective observational study

JBMR Plus
Background Optimization of sequential and combination treatment is crucial in shaping long-term management of postmenopausal osteoporosis (OP). Methods We conducted a 6-month prospective observational study on postmenopausal women with severe OP ...
G. Adami, E. Pedrollo, Maurizio Rossini, A. Fassio, V. Braga, E. Pasetto, F. Pollastri, C. Benini, O. Viapiana, Davide Gatti   +9 more
semanticscholar   +1 more source

Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2‐Year Randomized Study

Journal of Bone and Mineral Research, 2021
Increased bone turnover and rapid bone loss follow discontinuation of denosumab. We investigated the long‐term efficacy of zoledronate (ZOL) in maintaining bone mineral density (BMD) after discontinuation of denosumab.
Anne Sophie Sølling, T. Harsløf, B. Langdahl   +2 more
semanticscholar   +1 more source

Plain language summary of publication to understand the ROSALIA study: a new biosimilar denosumab for bone health

Therapeutic Advances in Musculoskeletal Disease
Summary What is this summary about? This plain language summary describes the results of a clinical study, ROSALIA , which was published in the Journal of Bone and Mineral Research in 2024. The ROSALIA study looked at whether biosimilar denosumab has the
Richard Eastell, Sławomir Jeka, Maryam Lustberg, Colin Edgerton, Paweł Żuchowski, Barbara Vogg   +5 more
doaj   +1 more source

Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours

Health Technology Assessment, 2013
Background: Denosumab offers an alternative, or additional, treatment for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumours.
J Ford, E Cummins, P Sharma, A Elders, F Stewart, R Johnston, P Royle, R Jones, C Mulatero, R Todd, G Mowatt   +10 more
doaj   +1 more source

Objective response of denosumab for multiple pulmonary metastases from giant cell tumor of bone: A case report and review of the literature

Current Problems in Cancer: Case Reports, 2021
A 23-year-old man received denosumab therapy for histologically proven multiple pulmonary metastases from a giant cell tumor of the distal femur after surgery.
Ikuo Kudawara, Shigeki Kakunaga, Koji Takami   +2 more
doaj   +1 more source